Akoya Biosciences (AKYA) Competitors $1.29 0.00 (0.00%) As of 07/8/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AKYA vs. MASS, FEIM, KEQU, RPID, OWLT, SEER, OPXS, PRE, NAUT, and INTTShould you be buying Akoya Biosciences stock or one of its competitors? The main competitors of Akoya Biosciences include 908 Devices (MASS), Frequency Electronics (FEIM), Kewaunee Scientific (KEQU), Rapid Micro Biosystems (RPID), Owlet (OWLT), Seer (SEER), Optex Systems (OPXS), Prenetics Global (PRE), Nautilus Biotechnology (NAUT), and inTEST (INTT). These companies are all part of the "measuring and control equipment" industry. Akoya Biosciences vs. Its Competitors 908 Devices Frequency Electronics Kewaunee Scientific Rapid Micro Biosystems Owlet Seer Optex Systems Prenetics Global Nautilus Biotechnology inTEST Akoya Biosciences (NASDAQ:AKYA) and 908 Devices (NASDAQ:MASS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk. Which has stronger valuation and earnings, AKYA or MASS? Akoya Biosciences has higher revenue and earnings than 908 Devices. 908 Devices is trading at a lower price-to-earnings ratio than Akoya Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkoya Biosciences$79.96M0.81-$55.37M-$0.97-1.33908 Devices$59.63M4.46-$72.21M-$0.54-13.74 Do insiders & institutionals hold more shares of AKYA or MASS? 79.4% of Akoya Biosciences shares are owned by institutional investors. Comparatively, 88.1% of 908 Devices shares are owned by institutional investors. 7.3% of Akoya Biosciences shares are owned by company insiders. Comparatively, 23.7% of 908 Devices shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is AKYA or MASS more profitable? 908 Devices has a net margin of -28.80% compared to Akoya Biosciences' net margin of -59.44%. 908 Devices' return on equity of -27.10% beat Akoya Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Akoya Biosciences-59.44% -487.85% -35.86% 908 Devices -28.80%-27.10%-20.49% Which has more risk & volatility, AKYA or MASS? Akoya Biosciences has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, 908 Devices has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500. Does the media prefer AKYA or MASS? In the previous week, 908 Devices had 5 more articles in the media than Akoya Biosciences. MarketBeat recorded 6 mentions for 908 Devices and 1 mentions for Akoya Biosciences. 908 Devices' average media sentiment score of 1.34 beat Akoya Biosciences' score of 0.00 indicating that 908 Devices is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akoya Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral 908 Devices 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer AKYA or MASS? Akoya Biosciences currently has a consensus target price of $2.51, suggesting a potential upside of 94.26%. 908 Devices has a consensus target price of $5.33, suggesting a potential downside of 28.12%. Given Akoya Biosciences' higher probable upside, analysts clearly believe Akoya Biosciences is more favorable than 908 Devices.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akoya Biosciences 0 Sell rating(s) 7 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00908 Devices 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Summary908 Devices beats Akoya Biosciences on 11 of the 16 factors compared between the two stocks. Get Akoya Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AKYA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKYA vs. The Competition Export to ExcelMetricAkoya BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$64.44M$3.06B$5.75B$9.55BDividend YieldN/A2.37%4.71%4.01%P/E Ratio-1.338.0820.8516.92Price / Sales0.81330.31461.42104.42Price / CashN/A42.6036.1858.54Price / Book8.608.328.655.87Net Income-$55.37M-$55.19M$3.25B$258.89M7 Day PerformanceN/A5.86%4.30%3.70%1 Month Performance-3.01%17.29%10.57%11.71%1 Year Performance-47.56%4.39%35.68%17.98% Akoya Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKYAAkoya Biosciences1.5279 of 5 stars$1.29flat$2.51+94.3%N/A$64.44M$79.96M-1.3390MASS908 Devices1.304 of 5 stars$6.96+3.9%$5.33-23.4%+33.7%$240.27M$59.63M-12.8960News CoverageFEIMFrequency Electronics1.5737 of 5 stars$23.22+8.2%N/A+107.9%$207.76M$69.81M9.40200High Trading VolumeKEQUKewaunee Scientific1.2602 of 5 stars$57.77+3.8%N/A+8.8%$164M$240.47M15.081,239Positive NewsRPIDRapid Micro Biosystems2.1389 of 5 stars$3.40-0.3%$8.00+135.3%+495.6%$149.47M$28.05M-3.30200Upcoming EarningsOWLTOwlet1.4314 of 5 stars$7.74-3.5%$10.25+32.4%+105.8%$132.53M$78.10M-5.41106News CoverageSEERSeer2.1076 of 5 stars$2.13+0.9%$3.00+40.8%+6.8%$124.21M$14.17M-1.51160OPXSOptex Systems1.9198 of 5 stars$12.73-8.9%N/A+56.3%$96.57M$33.99M17.9380High Trading VolumePREPrenetics Global1.7596 of 5 stars$8.07+2.0%$9.00+11.5%+39.2%$96.54M$30.62M-2.021High Trading VolumeNAUTNautilus Biotechnology3.0765 of 5 stars$0.73+0.3%$2.13+192.3%-73.7%$91.47MN/A-1.35130Positive NewsUpcoming EarningsINTTinTEST3.6187 of 5 stars$7.30-0.3%$12.00+64.4%-27.5%$91.21M$127.50M31.74320News Coverage Related Companies and Tools Related Companies MASS Competitors FEIM Competitors KEQU Competitors RPID Competitors OWLT Competitors SEER Competitors OPXS Competitors PRE Competitors NAUT Competitors INTT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKYA) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredIt’s my duty to share the “truth” I see behind this bible verseFormer CIA advisor Jim Rickards believes President Trump has just unlocked what the Bible foretold — a $150 tr...Paradigm Press | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akoya Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akoya Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.